Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Mizuho Securities Cuts Biogen's Price Target to $270 From $300, Citing Aduhelm Sales Estimates; Neutral Rating Kept

10/26/2021 | 05:36am EST


© MT Newswires 2021
All news about BIOGEN INC.
06:32aSage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Developm..
BU
12/06Goldman Sachs Starts Biogen at Neutral With $271 Price Target
MT
12/03Drugmakers cut prices by 62% on average to get China state insurance listing
RE
12/01Sage Therapeutics, Biogen Report Positive Data From Antidepressant Drug Candidate Zuran..
MT
12/01Viatris Wins Court Tussle Against Biogen as US Appeals Court Upholds Earlier Patent Rul..
MT
12/01Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the O..
BU
12/01Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the O..
CI
11/30Biogen Loses Appeals Court Bid to Revive Multiple Sclerosis Drug Patent
MT
11/30US Court of Appeals Affirms District Court Decision That Biogen's 2028 Tecfidera Patent..
MT
11/22Biogen's Alzheimer's Drug Reportedly Caused Brain Swelling in Over One-Third of Patient..
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 879 M - -
Net income 2021 1 657 M - -
Net Debt 2021 2 311 M - -
P/E ratio 2021 21,2x
Yield 2021 -
Capitalization 33 320 M 33 320 M -
EV / Sales 2021 3,28x
EV / Sales 2022 3,04x
Nbr of Employees 9 100
Free-Float 85,5%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Last Close Price 226,83 $
Average target price 347,93 $
Spread / Average Target 53,4%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Head-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors